Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…
Lunai Bioworks Inc.
Next earnings ≈ Aug 14, 2026 · est. from filing cadence
High return on equity (833.8%).
Rules-based read computed from SEC figures — no Anthropic key set. Add ANTHROPIC_API_KEY to .env.local for a full Claude analysis.
Lunai Bioworks Inc. shows $0.00 in FY2012 revenue, and 833.8% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
Sources: SEC EDGAR (CIK 0001527728, latest 10-Q filed 2026-05-15) · EODHD · rules-based read · as of 6/18/2026, 1:13:10 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$23.4M | -$116M | -$38.6M | -$81.6M | -$189M |
| Net income | -$26.7M | -$113M | -$39.7M | -$88.4M | -$178M |
| Diluted EPS | — | -$2.16 | -$0.71 | -$0.91 | -$1.08 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
501 tracked peers · median
| 2025-03-10 | William Anderson Wittekind 10% owner | Disposed (J) | 350K | |
| 2025-01-21 | van Tilburg Maurice Director | Award | 250K | |
| 2024-10-14 | Weinstein David Hershel Chief Executive Officer | Award | 250K |